Study the Biochemical Activities of Anti-HCV Drugs on Thioacetamide Induced Hepatic Fibrosis

The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats

“…Juxtamedullary collagen content increased significantly in the TAA treated group in this study which agreed with Mansour et al [ 10 ] who showed significant increase in the amount of collagen fibers in-between renal tubules and around renal glomeruli after TAA treatment as well. Moreover, significantly increased collagen and fibrin deposition in the renal medulla with focal mesangial cell proliferation and outstanding hepatic perivascular and peri-biliary deposition of collagen were noticed as well in the TAA supplemented group [ 26 , 44 ]. Mesangial cell proliferation was confirmed by estimating the expression of α-smooth muscle actin in the current study.…”

“…SFV plus DAC combination therapy was extensively investigated in different HCV genotypes and proved a high rate of safety, tolerance and effectiveness for the treatment of chronic hepatitis C [ 21 ]. Also, the same combination was investigated in TAA induced hepatitis and showed a great anti fibrotic effect by inhibiting TNF-α cytokine as well as a protective effects against oxidative stress and inflammation [ 26 ]. Previously, simultaneous kidney and liver transplantation followed by HCV treatment was the only possible treatment option for patients with advanced liver disease associated with nephropathy.…”

“…Evidence from recent studies valued the efficiency of SFV and DAC combination in treatment of HCV (approved) [ 14 , 21 , 22 ], as well as the potential effect (not yet approved) against corona virus disease 19 [ 23 - 25 ]. Also, Co-treatment with SFV and DAC combination restored the normal liver structure and function after TAA induction of liver damage [ 26 ]. However, the use of DAAs for treatment of patients with severe renal impairment is still challenging and not yet approved [ 27 ] although, many reports revealed good tolerance and unimportant adverse effects for their use in these patients [ 14 ].…”

“…However, the use of DAAs for treatment of patients with severe renal impairment is still challenging and not yet approved [ 27 ] although, many reports revealed good tolerance and unimportant adverse effects for their use in these patients [ 14 ]. And TAA exposure can lead to centrilobular death and liver cirrhosis which mimic the pathology induced by HCV [ 26 ]. Based on these findings, it was hypothesized that the use of DAAs might improve the renal dysfunction associated with TAA exposure or HCV liver affection.…”